首页 > 最新文献

Journal of Heart and Lung Transplantation最新文献

英文 中文
Enabling effective care, empowering discovery: Tackling the tough questions about advanced heart failure in adult congenital heart disease 促进有效护理,促进发现:解决成人先天性心脏病晚期心力衰竭的棘手问题
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-09-12 DOI: 10.1016/j.healun.2025.06.028
Christopher R. Broda MD , Katherine Kearney MBBS, PhD , S. Lucy Roche MB ChB, MD (research)
Many adults with moderate or complex congenital heart disease (CHD) develop chronic heart or circulatory failure syndromes, often becoming clinically apparent in their 30 s, 40 s, or 50 s and carrying a high risk of mortality. Although the pathophysiology of adult congenital heart disease-related heart failure (ACHD-HF) is highly heterogeneous, it is typically characterized by a prolonged pre-symptomatic phase. During this time, chronic compensatory mechanisms mask disease progression, making the severity of the condition difficult to recognize in a timely manner. This clinical challenge is compounded by fragmented care models, limited specialist resources, and persistent knowledge gaps. Consequently, patients are referred late for advanced therapies, contributing to the excess mortality, particularly in the context of transplant.
While it is recognized that excellent outcomes from transplant and mechanical circulatory support options are achievable in adult CHD patients, contemporary selection practices leave the population undertreated. To advance this cause, we convened a meeting at the 2025 International Society for Heart and Lung Transplantation 45th Annual Meeting & Scientific Sessions in Boston, Massachusetts. The meeting brought together more than 35 participants, including adult and pediatric cardiologists, surgeons, advanced practice providers, researchers, and trainees from North America, Europe and Australia. This diverse group shared opinions regarding priorities for research, education and patient advocacy.
A widely supported outcome was the development of an ACHD-HF specific professional community under the umbrella of ISHLT. This entity would serve as a collaborative home for those dedicated to addressing the knowledge gaps in ACHD-HF, advancing care, and improving outcomes for this growing and vulnerable population.
许多患有中度或复杂先天性心脏病(CHD)的成年人会出现慢性心脏或循环衰竭综合征,通常在30多岁、40多岁或50多岁时出现临床症状,死亡率很高。虽然成人先天性心脏病相关性心力衰竭(ACHD-HF)的病理生理是高度异质性的,但其典型特征是症状前期延长。在此期间,慢性代偿机制掩盖了疾病的进展,使病情的严重程度难以及时识别。分散的护理模式、有限的专家资源和持续的知识差距使这一临床挑战更加复杂。因此,患者接受先进治疗的时间较晚,导致死亡率过高,特别是在移植手术中。虽然人们认识到,移植和机械循环支持选择在成年冠心病患者中是可以实现的,但当代的选择实践使人群得不到充分治疗。为了推进这一事业,我们在马萨诸塞州波士顿举行的2025年国际心肺移植学会第45届年会和科学会议上召开了一次会议。会议汇集了超过35名与会者,包括来自北美、欧洲和澳大利亚的成人和儿科心脏病专家、外科医生、高级实践提供者、研究人员和受训人员。这个多元化的团体就研究、教育和患者倡导的优先事项分享了意见。一个得到广泛支持的结果是在ISHLT的保护下建立了一个ACHD-HF专门的专业社区。该实体将成为致力于解决ACHD-HF知识差距、推进护理和改善这一不断增长的弱势群体结局的人们的合作之家。
{"title":"Enabling effective care, empowering discovery: Tackling the tough questions about advanced heart failure in adult congenital heart disease","authors":"Christopher R. Broda MD ,&nbsp;Katherine Kearney MBBS, PhD ,&nbsp;S. Lucy Roche MB ChB, MD (research)","doi":"10.1016/j.healun.2025.06.028","DOIUrl":"10.1016/j.healun.2025.06.028","url":null,"abstract":"<div><div>Many adults with moderate or complex congenital heart disease (CHD) develop chronic heart or circulatory failure syndromes, often becoming clinically apparent in their 30 s, 40 s, or 50 s and carrying a high risk of mortality. Although the pathophysiology of adult congenital heart disease-related heart failure (ACHD-HF) is highly heterogeneous, it is typically characterized by a prolonged pre-symptomatic phase. During this time, chronic compensatory mechanisms mask disease progression, making the severity of the condition difficult to recognize in a timely manner. This clinical challenge is compounded by fragmented care models, limited specialist resources, and persistent knowledge gaps. Consequently, patients are referred late for advanced therapies, contributing to the excess mortality, particularly in the context of transplant.</div><div>While it is recognized that excellent outcomes from transplant and mechanical circulatory support options are achievable in adult CHD patients, contemporary selection practices leave the population undertreated. To advance this cause, we convened a meeting at the 2025 International Society for Heart and Lung Transplantation 45th Annual Meeting &amp; Scientific Sessions in Boston, Massachusetts. The meeting brought together more than 35 participants, including adult and pediatric cardiologists, surgeons, advanced practice providers, researchers, and trainees from North America, Europe and Australia. This diverse group shared opinions regarding priorities for research, education and patient advocacy.</div><div>A widely supported outcome was the development of an ACHD-HF specific professional community under the umbrella of ISHLT. This entity would serve as a collaborative home for those dedicated to addressing the knowledge gaps in ACHD-HF, advancing care, and improving outcomes for this growing and vulnerable population.</div></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"44 10","pages":"Pages 1679-1682"},"PeriodicalIF":6.0,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145047806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First-in-human operations require more than technical excellence 人类首次手术需要的不仅仅是技术上的卓越
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-09-12 DOI: 10.1016/j.healun.2025.06.017
Brent K. Winemiller , Joshua A. Daily , Paolla G. Anderson , Taufiek Konrad Rajab
{"title":"First-in-human operations require more than technical excellence","authors":"Brent K. Winemiller ,&nbsp;Joshua A. Daily ,&nbsp;Paolla G. Anderson ,&nbsp;Taufiek Konrad Rajab","doi":"10.1016/j.healun.2025.06.017","DOIUrl":"10.1016/j.healun.2025.06.017","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"44 10","pages":"Pages 1672-1673"},"PeriodicalIF":6.0,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145048228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tolerability and clinical efficacy of letermovir for primary cytomegalovirus prophylaxis after heart transplantation 莱替莫韦预防心脏移植术后原发性巨细胞病毒的耐受性和临床疗效。
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-09-11 DOI: 10.1016/j.healun.2025.08.023
Jennifer K.L. Chow MD, MS , Amanda R. Vest MBBS, MPH , David DeNofrio MD , David R. Snydman MD

Background

Letermovir (LET) is a newer antiviral that has successfully been used for primary cytomegalovirus (CMV) prophylaxis in kidney transplant recipients. Valganciclovir (VGC), the current first-line CMV antiviral, is effective at prophylaxis but carries a significant risk of myelotoxicity with related downstream consequences. We studied the tolerability and clinical effectiveness of LET for primary CMV prophylaxis after heart transplant (HT) and compared rates of neutropenia and CMV disease to a historical HT cohort.

Methods

All single-organ, first-time HTs at our center who gave informed consent and were eligible to receive primary CMV prophylaxis (not CMV donor/recipient seronegative) were included. Subjects were subsequently excluded if they needed renal replacement therapy or did not survive >72 hours post-HT. Outcomes were compared to a historical control group (N = 204) treated with VGC for CMV prophylaxis.

Results

Thirty-two patients completed 3 or 6 months of LET prophylaxis. There were no episodes of neutropenia while on LET compared to 15% (30/204) in the historical VGC group (p = 0.02). There were no breakthrough CMV deoxyribonucleic acid (DNA) infections compared to 3% (5/204) in the VGC group (p = 0.37). No patients stopped LET early due to adverse effects.

Conclusions

LET is well tolerated and shows comparable clinical effectiveness for primary CMV prophylaxis post-HT compared to a historical, predominantly VGC prophylaxis cohort. LET prophylaxis was associated with no cases of neutropenia nor breakthrough CMV DNAemia in this prospective cohort. Study of the cost-effectiveness of LET for primary CMV prophylaxis post-HT is warranted.
letermovir (LET)是一种较新的抗病毒药物,已成功用于肾移植受者原发性巨细胞病毒(CMV)的预防。缬更昔洛韦(VGC)是目前一线的巨细胞病毒抗病毒药物,具有有效的预防作用,但具有显著的骨髓毒性风险,并伴有相关的下游后果。我们研究了LET对心脏移植(HT)后原发性巨细胞病毒预防的耐受性和临床有效性,并比较了中性粒细胞减少症和巨细胞病毒疾病与历史HT队列的发病率。方法纳入本中心所有给予知情同意并有资格接受初级CMV预防治疗的单器官首次HTs(非CMV供体/受体血清阴性)。随后,如果受试者需要肾脏替代治疗,或在ht后存活不到72小时,则排除受试者。结果与使用VGC预防巨细胞病毒的历史对照组(N=204)进行比较。结果32例患者完成了3或6个月的LET预防治疗。与历史VGC组的15%(30/204)相比,LET期间没有中性粒细胞减少发作(p=0.02)。与VGC组的3%(5/204)相比,没有突破性的CMV DNA感染(p=0.37)。没有患者因不良反应而早期停用LET。结论:与历史上主要的VGC预防队列相比,let耐受性良好,在ht后原发性巨细胞病毒预防中显示出相当的临床效果。在这个前瞻性队列中,LET预防与中性粒细胞减少症和突破性巨细胞病毒dna血症无关。有必要研究LET对ht后原发性巨细胞病毒预防的成本效益。
{"title":"Tolerability and clinical efficacy of letermovir for primary cytomegalovirus prophylaxis after heart transplantation","authors":"Jennifer K.L. Chow MD, MS ,&nbsp;Amanda R. Vest MBBS, MPH ,&nbsp;David DeNofrio MD ,&nbsp;David R. Snydman MD","doi":"10.1016/j.healun.2025.08.023","DOIUrl":"10.1016/j.healun.2025.08.023","url":null,"abstract":"<div><h3>Background</h3><div>Letermovir (LET) is a newer antiviral that has successfully been used for primary cytomegalovirus (CMV) prophylaxis in kidney transplant recipients. Valganciclovir (VGC), the current first-line CMV antiviral, is effective at prophylaxis but carries a significant risk of myelotoxicity with related downstream consequences. We studied the tolerability and clinical effectiveness of LET for primary CMV prophylaxis after heart transplant (HT) and compared rates of neutropenia and CMV disease to a historical HT cohort.</div></div><div><h3>Methods</h3><div>All single-organ, first-time HTs at our center who gave informed consent and were eligible to receive primary CMV prophylaxis (not CMV donor/recipient seronegative) were included. Subjects were subsequently excluded if they needed renal replacement therapy or did not survive &gt;72 hours post-HT. Outcomes were compared to a historical control group (N = 204) treated with VGC for CMV prophylaxis.</div></div><div><h3>Results</h3><div>Thirty-two patients completed 3 or 6 months of LET prophylaxis. There were no episodes of neutropenia while on LET compared to 15% (30/204) in the historical VGC group (<em>p</em> = 0.02). There were no breakthrough CMV deoxyribonucleic acid (DNA) infections compared to 3% (5/204) in the VGC group (<em>p</em> = 0.37). No patients stopped LET early due to adverse effects.</div></div><div><h3>Conclusions</h3><div>LET is well tolerated and shows comparable clinical effectiveness for primary CMV prophylaxis post-HT compared to a historical, predominantly VGC prophylaxis cohort. LET prophylaxis was associated with no cases of neutropenia nor breakthrough CMV DNAemia in this prospective cohort. Study of the cost-effectiveness of LET for primary CMV prophylaxis post-HT is warranted.</div></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 1","pages":"Pages 148-156"},"PeriodicalIF":6.0,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk-informed allocation in heart transplantation 心脏移植的风险分配
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-09-10 DOI: 10.1016/j.healun.2025.09.001
Francis D. Pagani MD, PhD
{"title":"Risk-informed allocation in heart transplantation","authors":"Francis D. Pagani MD, PhD","doi":"10.1016/j.healun.2025.09.001","DOIUrl":"10.1016/j.healun.2025.09.001","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"44 12","pages":"Pages 1883-1885"},"PeriodicalIF":6.0,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145043629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combined heart-lung organ allocation: A glitch in the system 心肺器官组合分配:系统中的一个小故障。
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-09-09 DOI: 10.1016/j.healun.2025.08.024
Joshua A. Rushakoff MD, MPP , Chetan B. Patel MD , Richa Agarwal MD , Haoran Jiang MS , Jacob N. Schroder MD , Matthew G. Hartwig MD , John M. Reynolds MD , Adam D. DeVore MD, MHS
Organ allocation guidelines prioritize patients at risk of waitlist mortality. In the United States, both the heart and lung allocation systems were revised within the last ten years. There is no specific allocation system for patients listed for combined heart-lung transplant. With updates to the heart and lung allocation systems, we have observed that combined heart-lung transplant patients can face unnecessarily long wait times. A focused listing pathway to better prioritize potential combined heart-lung transplant recipients could help ensure the appropriate patients are transplanted effectively and efficiently.
器官分配指南优先考虑有等待死亡风险的患者。在美国,心脏和肺的分配系统在过去的十年里进行了修订。心肺联合移植患者名单没有具体的分配制度。随着心肺分配系统的更新,我们观察到合并心肺移植患者可能面临不必要的长时间等待。有针对性的列出途径,以更好地优先考虑潜在的联合心肺移植受者,有助于确保适当的患者得到有效和高效的移植。
{"title":"Combined heart-lung organ allocation: A glitch in the system","authors":"Joshua A. Rushakoff MD, MPP ,&nbsp;Chetan B. Patel MD ,&nbsp;Richa Agarwal MD ,&nbsp;Haoran Jiang MS ,&nbsp;Jacob N. Schroder MD ,&nbsp;Matthew G. Hartwig MD ,&nbsp;John M. Reynolds MD ,&nbsp;Adam D. DeVore MD, MHS","doi":"10.1016/j.healun.2025.08.024","DOIUrl":"10.1016/j.healun.2025.08.024","url":null,"abstract":"<div><div>Organ allocation guidelines prioritize patients at risk of waitlist mortality. In the United States, both the heart and lung allocation systems were revised within the last ten years. There is no specific allocation system for patients listed for combined heart-lung transplant. With updates to the heart and lung allocation systems, we have observed that combined heart-lung transplant patients can face unnecessarily long wait times. A focused listing pathway to better prioritize potential combined heart-lung transplant recipients could help ensure the appropriate patients are transplanted effectively and efficiently.</div></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"44 12","pages":"Pages 2032-2034"},"PeriodicalIF":6.0,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145035743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to “Comment on ‘A randomized trial of open lung protective ventilation compared to conventional mechanical ventilation in deceased organ donors’” 回复“关于‘在死亡器官供体中应用开放式肺保护通气与常规机械通气的随机对照试验’的评论”。
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-09-05 DOI: 10.1016/j.healun.2025.08.016
Lorraine B. Ware MD , Tatsuki Koyama PhD , Ciara M. Shaver MD, PhD , Michael A. Matthay MD
{"title":"Reply to “Comment on ‘A randomized trial of open lung protective ventilation compared to conventional mechanical ventilation in deceased organ donors’”","authors":"Lorraine B. Ware MD ,&nbsp;Tatsuki Koyama PhD ,&nbsp;Ciara M. Shaver MD, PhD ,&nbsp;Michael A. Matthay MD","doi":"10.1016/j.healun.2025.08.016","DOIUrl":"10.1016/j.healun.2025.08.016","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"44 12","pages":"Page 2041"},"PeriodicalIF":6.0,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
International Society for Heart and Lung Transplantation (ISHLT) Consensus Statement on Risk Stratification in Pulmonary Arterial Hypertension 国际心肺移植学会(ISHLT)关于肺动脉高压风险分层的共识声明。
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-09-05 DOI: 10.1016/j.healun.2025.04.015
Sandeep Sahay , Scott Visovatti , Adriano R. Tonelli , Nelson Villasmil Hernandez , Eric D. Austin , Roberto Badagliacca , Rolf M.F. Berger , Athénaïs Boucly , Yucheng Chen , Colin Church , Marion Delcroix , Allen D. Everett , Harrison W. Farber , Charles Fauvel , Mardi Gomberg-Maitland , Megan Griffiths , Francois Haddad , Yuchi Han , Anna Hemnes , Marius M. Hoeper , Raymond L. Benza
{"title":"International Society for Heart and Lung Transplantation (ISHLT) Consensus Statement on Risk Stratification in Pulmonary Arterial Hypertension","authors":"Sandeep Sahay ,&nbsp;Scott Visovatti ,&nbsp;Adriano R. Tonelli ,&nbsp;Nelson Villasmil Hernandez ,&nbsp;Eric D. Austin ,&nbsp;Roberto Badagliacca ,&nbsp;Rolf M.F. Berger ,&nbsp;Athénaïs Boucly ,&nbsp;Yucheng Chen ,&nbsp;Colin Church ,&nbsp;Marion Delcroix ,&nbsp;Allen D. Everett ,&nbsp;Harrison W. Farber ,&nbsp;Charles Fauvel ,&nbsp;Mardi Gomberg-Maitland ,&nbsp;Megan Griffiths ,&nbsp;Francois Haddad ,&nbsp;Yuchi Han ,&nbsp;Anna Hemnes ,&nbsp;Marius M. Hoeper ,&nbsp;Raymond L. Benza","doi":"10.1016/j.healun.2025.04.015","DOIUrl":"10.1016/j.healun.2025.04.015","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"44 11","pages":"Pages e73-e131"},"PeriodicalIF":6.0,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The evolving role of echocardiography in evaluating donor hearts on Ex Situ perfusion 超声心动图在评价供体心脏非原位灌注中的作用。
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-09-05 DOI: 10.1016/j.healun.2025.08.022
Christoph Knosalla , Natalia Solowjowa
{"title":"The evolving role of echocardiography in evaluating donor hearts on Ex Situ perfusion","authors":"Christoph Knosalla ,&nbsp;Natalia Solowjowa","doi":"10.1016/j.healun.2025.08.022","DOIUrl":"10.1016/j.healun.2025.08.022","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"44 12","pages":"Pages 2028-2029"},"PeriodicalIF":6.0,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival and primary graft dysfunction after ex-vivo lung perfusion: Why timing matters 离体肺灌注后的生存和原发性移植物功能障碍:为什么时间很重要。
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-09-04 DOI: 10.1016/j.healun.2025.08.019
Awab Ahmad MD, Aaron M. Williams MD
{"title":"Survival and primary graft dysfunction after ex-vivo lung perfusion: Why timing matters","authors":"Awab Ahmad MD,&nbsp;Aaron M. Williams MD","doi":"10.1016/j.healun.2025.08.019","DOIUrl":"10.1016/j.healun.2025.08.019","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 1","pages":"Pages 69-70"},"PeriodicalIF":6.0,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145007084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond the boundaries: Blood group ABO incompatible heart transplantation in older children 超越界限:ABO血型不相容的大龄儿童心脏移植。
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-09-04 DOI: 10.1016/j.healun.2025.08.018
Simon Urschel MD
{"title":"Beyond the boundaries: Blood group ABO incompatible heart transplantation in older children","authors":"Simon Urschel MD","doi":"10.1016/j.healun.2025.08.018","DOIUrl":"10.1016/j.healun.2025.08.018","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"44 12","pages":"Pages 1918-1919"},"PeriodicalIF":6.0,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145007078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Heart and Lung Transplantation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1